Search results
Results from the WOW.Com Content Network
Simnotrelvir/ritonavir (trade name Xiannuoxin) is a pharmaceutical drug used for the treatment of COVID-19. [2] Simnotrelvir/ritonavir is a combination drug of simnotrelvir, an inhibitor of SARS-CoV-2 3CL pro, and ritonavir, [3] a CYP3A inhibitor. It was developed by Simcere Pharmaceutical and conditionally approved in China by the National ...
Nirmatrelvir belongs to a family of 3C-like protease inhibitors developed in the late 2010s against feline coronavirus, while ritonavir is an antiretroviral drug developed in the 1980s and used since the 1990s to inhibit the enzyme that metabolizes other protease inhibitors.
COVID-19. Pfizer. 3C-like protease inhibitor (Nirmatrelvir) / inhibition of metabolism of nirmatrelvir (ritonavir) Nevirapine. HIV. non- nucleoside reverse transcriptase inhibitor. Nitazoxanide. Broad-spectrum antiviral.
U.S. health regulators on Friday authorized a new antibody drug that targets the omicron variant, a key step in restocking the nation's arsenal against the latest version of COVID-19. The Food and ...
Post-exposure prophylaxis, also known as post-exposure prevention (PEP), is any preventive medical treatment started after exposure to a pathogen in order to prevent the infection from occurring. It should be contrasted with pre-exposure prophylaxis, which is used before the patient has been exposed to the infective agent.
The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. [1] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy ...
Ritonavir. Ritonavir, sold under the brand name Norvir, is an antiretroviral medication used along with other medications to treat HIV/AIDS. [4][5][8] This combination treatment is known as highly active antiretroviral therapy (HAART). [8] Ritonavir is a protease inhibitor, though it now mainly serves to boost the potency of other protease ...
t. e. Omicron (B.1.1.529) is a variant of SARS-CoV-2 first reported to the World Health Organization (WHO) by the Network for Genomics Surveillance in South Africa on 24 November 2021. [10][11] It was first detected in Botswana and has spread to become the predominant variant in circulation around the world. [12]